Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.

Targeted oncology - 1 Sept 2024

Elhariri Ahmed, Patel Jaydeepbhai, Mahadevia Himil, Albelal Douaa, Ahmed Ahmed K, Jones Jeremy C, Borad Mitesh J, Babiker Hani

Abstract excerpt

The 5-year relative survival rate for pancreatic cancer is currently the lowest among all cancer types with a dismal 13%. A Kirsten rat sarcoma virus (KRAS) gene mutation is present in approximately 90% of patients with pancreatic cancer; however, KRAS-specific drugs are not yet widely used in clinical practice for pancreatic cancer, specifically the KRASG12D variant. Advances in genomic testing revealed an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Pancreatic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 39123077
DOI: 10.1007/s11523-024-01088-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.PMID 39123077Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read ↗

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.Semantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.